말라리아 백신 시장 전망(-2030년) : 약물, 백신 유형, 투여 경로, 유통 채널, 최종 사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Malaria Vaccine Market is accounted for $54.1 billion in 2023 and is expected to reach $369.5 billion by 2030 growing at a CAGR of 31.6% during the forecast period. Vaccines against malaria are medicines that offer protection against the infectious sickness carried by mosquitoes. The bite of a female Anopheles mosquito carrying the malaria virus transmits the disease, sometimes referred to as plasmodium infection. Sweating, fever, and chills are signs of this chronic illness. There are a few different ways to administer these vaccines: intramuscular, subcutaneous, and intradermal injections.

According to the WHO, there were around 229 million malaria infections and 409,000 fatalities worldwide in 2019. Malaria has primarily plagued tropical areas such as Africa, Asia, Central America, and South America.

Market Dynamics:

Driver:

High Incidence of malaria

Malaria has been a significant health concern for many years, particularly in tropical and subtropical regions. Several factors contribute to the prevalence of malaria, including climate change, drug resistance in mosquitoes and parasites, inadequate healthcare infrastructure, and socioeconomic factors. However, the rise in prevalence occurs due to changing environmental conditions or shifts in the effectiveness of existing prevention strategies. These factors contribute to the growth of the market.

Restraint:

Lack of healthcare infrastructure

People find it challenging to obtain vaccines due to restricted access to healthcare facilities resulting from inadequate infrastructure for healthcare. There aren't any clinics or hospitals in remote locations that are set up to properly store and give immunizations. Inadequate healthcare systems may also result in restricted availability of health education and immunization awareness initiatives. Low vaccination uptake and vaccine hesitancy may result from this lack of knowledge. This is the element impeding the market's expansion.

Opportunity:

Increase in the number of research and development activities

Developments in vaccination cost, safety, and effectiveness have an impact on market expansion. Public and commercial research investments have an impact on the availability of more recent and potent vaccinations. Furthermore, particularly in environments with limited resources, government and international health agency support can have a major influence on the uptake and dissemination of malaria vaccinations. These are the variables affecting the market's expansion.

Threat:

High cost of medication development

The process of developing a vaccine necessitates significant financial investments due to the rigorous research, clinical trials, and regulatory procedures involved. The sustainability of mass production and distribution is impacted if the cost of manufacturing is high. Long-term efforts to get the vaccination to people who need it most could be hampered by it. Pharmaceutical firms, governments, and organizations that sponsor these initiatives have difficulties because to the exorbitant expenses.

COVID-19 Impact:

The manufacture and delivery of medical goods, especially those required for the prevention and treatment of malaria, were hampered by the worldwide interruptions in supply chains brought about by COVID-19. This impacted the supply of diagnostic instruments, antimalarial medications, and bed nets sprayed with insecticide. Lockdowns, travel bans, and limits on face-to-face encounters all caused interruptions to clinical studies for malaria vaccinations. As a result, there has been a delay in testing, findings analysis, and gaining regulatory permissions.

The anopheles species segment is expected to be the largest during the forecast period

The anopheles species segment is expected to be the largest during the forecast period. The transmission of malaria is directly addressed by vaccination against the anopheles species. It may considerably slow the transmission of malaria by lessening the mosquito's capacity to disseminate the infection. Research on vaccinations against the malaria parasite itself is ongoing, however these efforts would be aided by the development of a vaccine against the anopheles species.

The intramuscular segment is expected to have the highest CAGR during the forecast period

The intramuscular segment is expected to have the highest CAGR during the forecast period. For medical experts, administering a vaccination intramuscularly is a rather simple process. Specialized training beyond normal injection procedures is not needed. When injected intramuscularly, certain vaccinations are more stable and maintain their effectiveness more effectively. This is particularly important for vaccinations against illnesses that are common in areas without easy access to refrigeration or healthcare services.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Due of the disease's extensive effects, efforts have been made globally to develop and implement malaria vaccinations. Because of the decreased risk within the continent, the focus in this region has mostly been on preventive methods for visitors to malaria-prone regions rather than universal immunization. The key tactics for people visiting areas where malaria is endemic continue to be preventing mosquito bites and using antimalarial drugs.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to the increasing number of malarial infections, rising population and increasing government initiative for disease control. To create more potent malaria vaccines, academic institutions, pharmaceutical firms, and international health organizations have been working nonstop. In an effort to increase effectiveness, some ongoing research focuses on alternate vaccination strategies that target various phases of the malaria parasite's lifecycle.

Key players in the market:

Some of the key players in Malaria Vaccine market include Taj Pharmaceuticals Limited, Sanofi, Actiza Pharmaceutical Private Limited, Ipca Laboratories Ltd., Sumaya Biotech, Hikma Pharmaceuticals PLC, Bliss GVS Pharma Ltd., Amneal Pharmaceuticals LLC, Strides Pharma Science Limited, VLP Therapeutics, Novartis AG, Pfizer Inc., Mylan N.V., Zydus Cadila, Cipla Inc., Sun Pharmaceutical Industries Ltd., Ipca Laboratories Ltd. and GeoVax.

Key Developments:

In February 2023, Sun Pharmaceutical Industries Ltd., one of India's leading pharmaceutical companies, has announced the acquisition of a 26.09% stake in Agatsa Software Pvt. Ltd. and a 27.39% stake in Remidio Innovative Solutions Pvt. Ltd., both of which are digital health startups.

In November 2022, Novartis and Medicines for Malaria Venture (MMV) have announced plans to advance a ganaplacide/lumefantrine- solid dispersion formulation (SDF) into a Phase III clinical trial to treat individuals with acute uncomplicated malaria caused by Plasmodium falciparum.

Agents Covered:

• Anopheles Species
• Plasmodium Vivax
• Plasmodium Falciparum
• Other Agents

Vaccine Types Covered:

• Pre-Erythrocytic Vaccine
• Erythrocytic Vaccine
• Multi-antigen Vaccine
• Other Vaccine Types

Route of Administrations Covered:

• Intramuscular
• Subcutaneous
• Intradermal

Distribution Channels Covered:

• Retail Pharmacy
• Online Pharmacy
• Hospital Pharmacy
• Other Distribution Channels

End Users Covered:

• Hospitals
• Specialty Clinics
• Homecare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Malaria Vaccine Market, By Agent

• 5.1 Introduction
• 5.2 Anopheles Species
• 5.3 Plasmodium Vivax
• 5.4 Plasmodium Falciparum
• 5.5 Other Agents

6 Global Malaria Vaccine Market, By Vaccine Type

• 6.1 Introduction
• 6.2 Pre-Erythrocytic Vaccine
• 6.3 Erythrocytic Vaccine
• 6.4 Multi-antigen Vaccine
• 6.5 Other Vaccine Types

7 Global Malaria Vaccine Market, By Route of Administration

• 7.1 Introduction
• 7.2 Intramuscular
• 7.3 Subcutaneous
• 7.4 Intradermal

8 Global Malaria Vaccine Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Retail Pharmacy
• 8.3 Online Pharmacy
• 8.4 Hospital Pharmacy
• 8.5 Other Distribution Channels

9 Global Malaria Vaccine Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Specialty Clinics
• 9.4 Homecare
• 9.5 Other End Users

10 Global Malaria Vaccine Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Taj Pharmaceuticals Limited
• 12.2 Sanofi
• 12.3 Actiza Pharmaceutical Private Limited
• 12.4 Ipca Laboratories Ltd.
• 12.5 Sumaya Biotech
• 12.6 Hikma Pharmaceuticals PLC
• 12.7 Bliss GVS Pharma Ltd.
• 12.8 Amneal Pharmaceuticals LLC
• 12.9 Strides Pharma Science Limited
• 12.10 VLP Therapeutics
• 12.11 Novartis AG
• 12.12 Pfizer Inc.
• 12.13 Mylan N.V.
• 12.14 Zydus Cadila
• 12.15 Cipla Inc.
• 12.16 Sun Pharmaceutical Industries Ltd.
• 12.17 Ipca Laboratories Ltd.
• 12.18 GeoVax